Over 450 Total Lots Up For Auction at Three Locations - CO 05/12, PA 05/15, NY 05/20

DeVilbiss Sponsors Clinical Trial Confirming Effectiveness of SmartFlex Technology

Press releases may be edited for formatting or style | July 06, 2011
SOMERSET, PA - July 5, 2011 - DeVilbiss Healthcare recently sponsored a randomized, double-blind, crossover clinical study which confirmed the effectiveness of DeVilbiss SmartFlex Technology, a new exhalation pressure relief solution to enhance patient comfort.

Positive Airway Pressure (PAP) represents the gold standard in the treatment of Obstructive Sleep Apnea (OSA). In recent years, pressure modification has become accepted as an important feature improving patients' comfort and compliance. However, there has been some speculation that excessive pressure relief may compromise the effectiveness of therapy.

The study confirmed SmartFlex Technology to be equally effective to standard Auto-PAP therapy in that respiratory events and oxygen saturation during sleep were normalized among the participants. In addition, treatment with SmartFlex showed a lower leak rate, which likely contributes to the greater subject acceptance rates. As expected, both modalities resulted in improved daytime alertness, but improved daytime energy levels, ability to relax and nocturnal
stats Advertisement
DOTmed text ad

Training and education based on your needs

Stay up to date with the latest training to fix, troubleshoot, and maintain your critical care devices. GE HealthCare offers multiple training formats to empower teams and expand knowledge, saving you time and money

stats

sleep were also demonstrated with SmartFlex Technology.

The study included 28 patients with a recent diagnosis of OSA who agreed to participate in the research study. Patients were randomly assigned to Auto-PAP (with or without SmartFlex) for two weeks and were then switched for continued therapy for an additional two weeks. While all participants experienced treatment with and without SmartFlex, both participants and researchers were blinded to the assignment of SmartFlex.

The study results were presented at the Associated Professional Sleep Society's 2011 SLEEP Conference and Exhibition in Minneapolis by the Principal Investigator of the study, Dr. Leon Rosenthal, M.D. of Sleep Medicine Associates of Texas, P.A.

"Patient comfort and acceptance of therapy is critical to establishing an adherent patient," said Mike Marcinek, VP of Sales & Marketing - Sleep Solutions at DeVilbiss Healthcare. "We are very excited to see that there was improvement in sleep, relaxation and lower leak rates while on SmartFlex. With the objective clinical results appearing to show parity between the two therapies, there is a tremendous amount of subjective data currently being analyzed. We are excited to review all the findings with the goal of continuing to provide optimal solutions to patients."

DeVilbiss SmartFlex Technology provides three pressure relief drops and six rounding settings to ease inhale and exhale transitions. The SmartFlex transitions can be adjusted with DeVilbiss' patented Flow Rounding™ Technology to make the pressure drop and the corresponding increase feel even more natural to each patient. SmartFlex Technology is available exclusively on the DeVilbiss IntelliPAP® AutoAdjust® and IntelliPAP Standard Plus PAP Systems.

You Must Be Logged In To Post A Comment